{
    "organizations": [],
    "uuid": "5202933207c149de22c143369d51bc88eaa4f842",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abide-and-celgene-enter-worldwide/brief-abide-and-celgene-enter-worldwide-license-agreement-for-abx-1772-idUSFWN1RA0D1",
    "ord_in_thread": 0,
    "title": "BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "  Updated 10 minutes ago BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772 Reuters Staff \n  Celgene Corp: \n* ABIDE AND CELGENE ENTER WORLDWIDE LICENSE AGREEMENT FOR ABX-1772 \n* ‍ABIDE THERAPEUTICS SAYS GRANTED CELGENE AN EXCLUSIVE WORLDWIDE LICENSE FOR ABX-1772, A PRECLINICAL DRUG CANDIDATE DISCOVERED BY ABIDE​ \n* ‍ABIDE THERAPEUTICS SAYS ABIDE RECEIVED UNDISCLOSED PAYMENT AND WILL BE ENTITLED TO CERTAIN MILESTONE PAYMENTS AND ROYALTIES ON COMMERCIAL SALES​ \n* ‍ABIDE THERAPEUTICS SAYS ABIDE HAS REGAINED EX-US RIGHTS TO ABX-1431 FROM CELGENE​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-28T14:24:00.000+03:00",
    "crawled": "2018-03-28T14:48:22.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "celgene",
        "enter",
        "worldwide",
        "license",
        "agreement",
        "reuters",
        "staff",
        "celgene",
        "corp",
        "abide",
        "celgene",
        "enter",
        "worldwide",
        "license",
        "agreement",
        "therapeutic",
        "say",
        "granted",
        "celgene",
        "exclusive",
        "worldwide",
        "license",
        "preclinical",
        "drug",
        "candidate",
        "discovered",
        "therapeutic",
        "say",
        "abide",
        "received",
        "undisclosed",
        "payment",
        "entitled",
        "certain",
        "milestone",
        "payment",
        "royalty",
        "commercial",
        "therapeutic",
        "say",
        "abide",
        "regained",
        "right",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}